US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-757-01 D-0240-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-756-01 D-0239-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-755-01 D-0238-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-271-30 D-0237-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-270-30 D-0236-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-269-30 D-0235-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-268-30 D-0234-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-267-30 D-0233-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-266-30 D-0232-2025
Class II · Moderate risk Ongoing

Atomoxetine Capsules

Reason CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-265-30 D-0231-2025
Class I · High risk Ongoing

SinuCleanse Soft Tip NETI POT Nasal Wash System

Reason Microbial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureus

Ascent Consumer Products Inc. D-0301-2025
Class I · High risk Ongoing

SinuCleanse Premixed SALINE PACKETS

Reason Microbial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureus

Ascent Consumer Products Inc. D-0300-2025
Class II · Moderate risk Ongoing

HydrALAZINE Hydrochloride

Reason Failed Impurities/Degradation Specifications

Sky Packaging NDC 63739-328-10 D-0220-2025
Class II · Moderate risk Ongoing

HydrALAZINE Hydrochloride

Reason Failed Impurities/Degradation Specifications

Sky Packaging NDC 63739-327-10 D-0219-2025
Class II · Moderate risk Ongoing

Timolol Maleate Ophthalmic Solution USP

Reason Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

FDC Limited NDC 64980-514-05 D-0214-2025
Class II · Moderate risk Ongoing

Carvedilol Tablets

Reason CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-164-05 D-0216-2025
Class II · Moderate risk Ongoing

Carvedilol Tablets

Reason CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-165-05 D-0215-2025
Class I · High risk Ongoing

Phenylephrine HCl Injection

Reason Presence of Particulate Matter.

Provepharm Inc. D-0230-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0228-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0227-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0226-2025
Class II · Moderate risk Ongoing

Irbesartan Tablets USP

Reason Out of Specification for Dissolution

AvKARE NDC 50268-442-15 D-0224-2025
Class II · Moderate risk Ongoing

Inflectra

Reason cGMP Deviations: Product intended for quarantine was inadvertently distributed.

McKesson NDC 0069-0809-01 D-0213-2025
Class II · Moderate risk Ongoing

Granix

Reason Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit

Teva Pharmaceuticals USA, Inc NDC 63459-910-11 D-0218-2025